Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 7, 2023
Event: Closing of a previously announced public offering of equity securities.
Key Financial Metrics
Gross Proceeds: Approximately $4.5 million.
Offering Price: $2.00 per share of Common Stock (combined with warrants); $1.9999 per Pre-Funded Warrant (combined with warrants).
Placement Agent Fees: 5.5% of gross proceeds.
Legal Expense Reimbursement: Up to $75,000.
Non-Accountable Expense Allowance: Up to $15,000.
Tail Fee (H.C. Wainwright & Co.): $307,580 cash plus warrants for 131,820 shares.
Net Proceeds: Not explicitly stated; filing notes proceeds are before deducting fees and expenses.
Material Changes and Offering Details
The Company closed an offering consisting of the following securities:
- Common Stock: 600,000 shares.
- Pre-Funded Warrants: 1,650,000 warrants exercisable for 1,650,000 shares at $0.0001 per share.
- Series C Common Warrants: 2,250,000 warrants exercisable for 2,250,000 shares at $2.00 per share; expire in 2 years.
- Series D Common Warrants: 2,250,000 warrants exercisable for 2,250,000 shares at $2.00 per share; expire in 5 years.
Each unit sold included one share of Common Stock (or Pre-Funded Warrant) paired with one Series C and one Series D warrant. The Pre-Funded Warrants were exercised immediately upon closing.
Management Commentary and Use of Proceeds
The Company intends to use the net proceeds primarily for:
- Working capital and general corporate purposes.
- Research and development.
- Trial preparation expenses.
- Retention and severance payments to certain employees or former employees.
Placement Agents: A.G.P./Alliance Global Partners (lead) and Brookline Capital Markets (co-agent).
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 5.5% placement fee, legal reimbursements, and the $307,580 tail fee.
- Confirm the dilution impact of the 2,250,000 Series C and Series D warrants, noting their immediate exercisability at $2.00.
- Review the specific terms of the Tail Warrants issued to H.C. Wainwright & Co., which have a higher exercise price of $2.50.
- Assess the Company's cash runway given the stated use of proceeds for trial preparation and employee severance.
- Check subsequent filings for the registration status of the Tail Warrants, which were issued under Section 4(a)(2) exemption.